Gabriela Kłodowska-Duda

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 137 citations · Full text

Large-scale replication and heterogeneity in Parkinson disease genetic loci

Manu Sharma, John P. A. Ioannidis, Jan Aasly et al. · Neurology · 2012 · 130 citations · Full text

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications

Monika Białecka, Mateusz Kurzawski, Gabriela Kłodowska-Duda et al. · Pharmacogenetics and Genomics · 2008 · 98 citations